Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Explorative Study of Tolerability and Pharmacokinetics of SU011248 In Combination With Docetaxel As First-Line Treatment in Patients With Breast Cancer.

Next Previous
Trial Profile

An Explorative Study of Tolerability and Pharmacokinetics of SU011248 In Combination With Docetaxel As First-Line Treatment in Patients With Breast Cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Sunitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 01 Apr 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
  • 01 Apr 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
  • 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top